ehealth digital library

Digital library of
the Tanzania
health
community

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

Cech, P. G., Aebi, T., Abdallah, M. S., Mpina, M., Machunda, E. B., Westerfeld, N., Stoffel, S. A., Zurbriggen, R., Pluschke, G., Tanner, M., Daubenberger, C., Genton, B. and Abdulla, S. (2011) Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PloS one, 6 (7). pp. 1-11. ISSN 1932-6203

[img]
Preview
PDF
Virosome-formulated_Plasmodium_falciparum.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (558kB)

Abstract

BACKGROUND

This trial was conducted to evaluate the safety and immunogenicity of two virosome formulated malaria peptidomimetics derived from Plasmodium falciparum AMA-1 and CSP in malaria semi-immune adults and children.

METHODS

The design was a prospective randomized, double-blind, controlled, age-deescalating study with two immunizations. 10 adults and 40 children (aged 5-9 years) living in a malaria endemic area were immunized with PEV3B or virosomal influenza vaccine Inflexal®V on day 0 and 90.

RESULTS

No serious or severe adverse events (AEs) related to the vaccines were observed. The only local solicited AE reported was pain at injection site, which affected more children in the Inflexal®V group compared to the PEV3B group (p = 0.014). In the PEV3B group, IgG ELISA endpoint titers specific for the AMA-1 and CSP peptide antigens were significantly higher for most time points compared to the Inflexal®V control group. Across all time points after first immunization the average ratio of endpoint titers to baseline values in PEV3B subjects ranged from 4 to 15 in adults and from 4 to 66 in children. As an exploratory outcome, we found that the incidence rate of clinical malaria episodes in children vaccinees was half the rate of the control children between study days 30 and 365 (0.0035 episodes per day at risk for PEV3B vs. 0.0069 for Inflexal®V; RR  = 0.50 [95%-CI: 0.29-0.88], p = 0.02).

CONCLUSION

These findings provide a strong basis for the further development of multivalent virosomal malaria peptide vaccines.

TRIAL REGISTRATION

ClinicalTrials.gov NCT00513669.

Item Type: Article
Keywords: Virosome, Plasmodium falciparum, Malaria vaccine, Malaria immunity, Malaria prevention, Malaria control
Subjects: Biomedical Science > Immunology
Malaria > Vaccines
Divisions: Ifakara Health Institute > Biomedical
Depositing User: Mr Joseph Madata
Date Deposited: 17 Jul 2012 09:17
Last Modified: 16 Aug 2012 15:57
URI: http://ihi.eprints.org/id/eprint/14

Actions (login required)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics